Maximizing Data Quantity and Quality in Remote Alzheimer's Assessments

Alzheimer’s Disease studies generally have low success rates so when the COVID-19 pandemic required clinical trials to change to remote administration models, it became more critical than ever to maximize the quantity and quality of data in these studies.

Signant Health’s David Miller outlines considerations for optimizing the quality and reliability of remote outcomes assessment data, including validating scales for audio and/or video administration, confirming if input is needed from patients and/or caregivers, ensuring all participants understand their roles, considering study drug administration, meeting site location needs, and respecting the patient’s discomfort with an at-home administer during COVID-19.